Oslo-headquartered venture capital firm NeoMed Management has held a first close of its fourth life sciences fund on €38 million ($50 million).
NeoMed Innovation IV has a final target of €100 million. Investors in the fund to date include Norwegian fund of funds Argentum Fondsinvesteringer, Swedish pension fund Tredje AP-Fonden and UK-based Höegh Capital Partners.
The new fund will invest in emerging growth companies in the biotechnology, pharmaceutical and diagnostics industries. In addition, the fund will invest in companies developing medical instruments, reagents and devices.
The firm’s third fund, NeoMed Innovation III, closed on €42 million in 2001 and has made commitments to ten companies, two of which have been exited to date.
The new fund will continue to seek investment opportunities as lead investor in Scandinavia or Switzerland, or as an active syndicate member elsewhere in Europe and the US.
NeoMed Management has offices in Oslo, Geneva and New York.